DEXCOM INC

Dexcom reports mixed H1 2026 results, showing steady CGM revenue growth, new Omnipod‑compatible sensor and a roadmap for AI‑driven AID expansion.

DexCom’s G7 CGM shows a 0.7% HbA1c drop and 62% time‑in‑range for non‑insulin type‑2 diabetics, while an insider sale highlights market dynamics and future Medicare coverage.